"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
| Descriptor ID |
D011960
|
| MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 2 | 8 |
| 1996 | 3 | 4 | 7 |
| 1997 | 9 | 4 | 13 |
| 1998 | 6 | 4 | 10 |
| 1999 | 7 | 7 | 14 |
| 2000 | 10 | 5 | 15 |
| 2001 | 14 | 6 | 20 |
| 2002 | 7 | 6 | 13 |
| 2003 | 10 | 5 | 15 |
| 2004 | 8 | 8 | 16 |
| 2005 | 13 | 10 | 23 |
| 2006 | 7 | 10 | 17 |
| 2007 | 11 | 4 | 15 |
| 2008 | 3 | 7 | 10 |
| 2009 | 6 | 11 | 17 |
| 2010 | 12 | 8 | 20 |
| 2011 | 8 | 11 | 19 |
| 2012 | 10 | 7 | 17 |
| 2013 | 5 | 9 | 14 |
| 2014 | 3 | 7 | 10 |
| 2015 | 10 | 7 | 17 |
| 2016 | 5 | 2 | 7 |
| 2017 | 3 | 9 | 12 |
| 2018 | 4 | 11 | 15 |
| 2019 | 3 | 6 | 9 |
| 2020 | 2 | 7 | 9 |
| 2021 | 3 | 6 | 9 |
| 2022 | 0 | 9 | 9 |
| 2023 | 1 | 8 | 9 |
| 2024 | 5 | 6 | 11 |
| 2025 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 Aug 27; 17(813):eadq5492.
-
Genetics-nutrition interactions control diurnal enhancer-promoter dynamics and liver lipid metabolism. Cell Metab. 2025 Oct 07; 37(10):1961-1979.e7.
-
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. Oncologist. 2025 Jul 04; 30(7).
-
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. J Natl Cancer Inst. 2025 May 01; 117(5):889-897.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2- metastatic breast cancer: A Flatiron Health database analysis. Breast. 2025 Jun; 81:104448.
-
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN. Breast Cancer Res. 2025 Feb 14; 27(1):22.
-
Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2025 Apr; 43(10):1229-1239.
-
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study. Clin Cancer Res. 2024 Dec 02; 30(23):5304-5313.
-
Real-world quality-of-life of patients with HR+/HER2-?advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat. 2025 Feb; 209(3):613-627.